Worth reading
75Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
9798
¥ million (year-on-year increase in net sales)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFiscal year ending March 2026, full year14 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥132,186 million+8.0%
Operating profit¥3,313 million+5.0%
Ordinary income¥3,193 million+1.0%
Net income¥1,070 million -15.2%net income attributable to owners of the parent
Operating profit margin2.5 %
Full-year earnings forecast
Net Sales
¥136,000 million
EBITDA
¥6,420 million
Operating profit
¥3,000 million
Ordinary income
¥2,700 million
Profit attributable to owners of the parent
¥1,000 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Profit growth was secured, but the plan was not achievedBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Year on year
Net Sales
Community Pharmacy Network+JPY 10,212 million
Rental Facilities-JPY 88 million
Catered meals-JPY 70 million
Home-visit nursing-JPY 6 million
Other-JPY 247 million
Operating profit
Community Pharmacy Network+JPY 399 million
Rental Facilities-JPY 34 million
Catered meals-¥28 million
Home-visit nursing+JPY 7 million
Other-JPY 183 million
Versus plan
Net Sales
Community Pharmacy Network+JPY 7,080 million
Rental Facilities-JPY 202 million
Catered meals-JPY 10 million
Home-visit nursing-JPY 7 million
Other-JPY 173 million
Operating profit
Community Pharmacy Network+¥52 million
Rental Facilities-JPY 71 million
Catered meals-¥25 million
Home-visit nursing-JPY 5 million
Other-JPY 37 million
New initiatives
- Formulation of the 7th Medium-Term Management Plan
- Build a customer management platform and establish a cross-selling structure
- Organize and standardize service offerings in the food, housing, sleep, and prevention fields, and introduce them at priority stores
- Strengthen alliances with manufacturing partners and expand the range of products handled
- Promote company-wide digital transformation and integrate customer and transaction data
Key KPIsA metric the company considers important as a management benchmark.
- Number of member pharmacies12,003 EngagementsYear on year against the same period last year+1,000 cases, +9.1% versus the end of the previous fiscal year
- Number of stores adopting the digital shift6,658 storesYear on year against the same period last year+638 stores, +10.6% versus the end of the previous fiscal year
- Number of stores purchasing pharmaceutical manufacturing and sales products9,082 storesYear on year against the same period last year+1,901 stores, +26.5% year on year
- Number of stores using pharmaceutical logistics services3,690 storesYear on year against the same period last year+2,118 stores, +134.7% versus the end of the previous fiscal year
- LINE Official Account followers209 10,000 peopleYear on year against the same period last year+630,000 people
Unit price and quantity metricsThese figures show sales broken down by price and volume.
All Stores
Number of prescriptions
10,206 thousand prescriptions+1.9%
Prescription Unit Price
10,698 JPY/prescription+4.0%
Drug cost per prescription
8,186 JPY/prescription+4.3%
Technical fee per prescription
2,512 JPY/prescription+3.2%
Existing stores
Number of prescriptions
9,508 thousand prescriptions-1.7%
Prescription Unit Price
10,766 JPY/prescription+5.0%
Segment results
Community Pharmacy Network Business
Net Sales
¥127,180 million+8.7%
Operating profit
¥6,025 million+7.1%
Rental and equipment-related businesses, food services, and home-visit nursing businesses
Net Sales
¥6,005 million-2.7%
Operating profit
¥115 million-32.8%
Medium-term management plan targets
Seventh Medium-Term Management Plan
Target fiscal yearFiscal year ending March 2030
Operating profit
50 Hundreds of millions of yen
ROE
11 %
Number of support cases
25,000 Facility
Market coverage
40 %
Financial targets
ROE
Actual results for the fiscal year ending March 20266.4%
Target for the fiscal year ending March 203011%
Target for the fiscal year ending March 203515%
Market Size / Share
Generic drug market sizeApproximately JPY 1.5 trillion
Market covered by products sold by the companyApproximately JPY 540 billion
Market coverage
Fiscal year ending March 2026Approximately 25%
Fiscal year ending March 2030Approximately 40%
Fiscal year ending March 203575～80%
Number of stores and locations
Number of community pharmacy stores
End of period472 Location
During the period
New Store Openings17
Store closures and business transfers11
M&A9
Capital expenditures
120 JPY hundred million four-year cumulative plan through the fiscal year ending March 2030
Annual Dividend
Fiscal year ending March 2026
Annual¥12 per share
Forecast for the fiscal year ending March 2027
Annual¥12 per share
Payout ratio
Fiscal year ending March 202632.7 %
Forecast for the fiscal year ending March 202735.1 %
Acquisition of treasury shares
Flexible share repurchases (the specific repurchase limit, number of shares, and period were Not disclosed)| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Fiscal year ending March 2026, full year |
| Net Sales | ¥132,186 million (YoY +8.0%) |
| Operating profit | ¥3,313 million (YoY +5.0%) |
| Ordinary income | ¥3,193 million (YoY +1.0%) |
| Net income | ¥1,070 million (net income attributable to owners of the parent) (YoY -15.2%) |
| Operating profit margin | 2.5 % |
| Full-year earnings forecast | Net Sales ¥136,000 million / EBITDA ¥6,420 million / Operating profit ¥3,000 million / Ordinary income ¥2,700 million / Profit attributable to owners of the parent ¥1,000 million |
| Self-assessment against the plan | Profit growth was secured, but the plan was not achieved |
| Segment results | Community Pharmacy Network Business Net Sales ¥127,180 million (YoY +8.7%) / Operating profit ¥6,025 million (YoY +7.1%) / Rental and equipment-related businesses, food services, and home-visit nursing businesses Net Sales ¥6,005 million (YoY -2.7%) / Operating profit ¥115 million (YoY -32.8%) |
| Breakdown of Factors Affecting the Change | Year on year Net Sales Community Pharmacy Network +JPY 10,212 million / Rental Facilities -JPY 88 million / Catered meals -JPY 70 million / Home-visit nursing -JPY 6 million / Other -JPY 247 million / Operating profit Community Pharmacy Network +JPY 399 million / Rental Facilities -JPY 34 million / Catered meals -¥28 million / Home-visit nursing +JPY 7 million / Other -JPY 183 million / Versus plan Net Sales Community Pharmacy Network +JPY 7,080 million / Rental Facilities -JPY 202 million / Catered meals -JPY 10 million / Home-visit nursing -JPY 7 million / Other -JPY 173 million / Operating profit Community Pharmacy Network +¥52 million / Rental Facilities -JPY 71 million / Catered meals -¥25 million / Home-visit nursing -JPY 5 million / Other -JPY 37 million |
| Key KPIs | Indicator name Number of member pharmacies / Value 12,003 Engagements / Year on year against the same period last year +1,000 cases, +9.1% versus the end of the previous fiscal year, Indicator name Number of stores adopting the digital shift / Value 6,658 stores / Year on year against the same period last year +638 stores, +10.6% versus the end of the previous fiscal year, Indicator name Number of stores purchasing pharmaceutical manufacturing and sales products / Value 9,082 stores / Year on year against the same period last year +1,901 stores, +26.5% year on year, Indicator name Number of stores using pharmaceutical logistics services / Value 3,690 stores / Year on year against the same period last year +2,118 stores, +134.7% versus the end of the previous fiscal year, Indicator name LINE Official Account followers / Value 209 10,000 people / Year on year against the same period last year +630,000 people |
| Unit price and quantity metrics | All Stores Number of prescriptions 10,206 thousand prescriptions (YoY +1.9%) / Prescription Unit Price 10,698 JPY/prescription (YoY +4.0%) / Drug cost per prescription 8,186 JPY/prescription (YoY +4.3%) / Technical fee per prescription 2,512 JPY/prescription (YoY +3.2%) / Existing stores Number of prescriptions 9,508 thousand prescriptions (YoY -1.7%) / Prescription Unit Price 10,766 JPY/prescription (YoY +5.0%) |
| Number of stores and locations | Number of community pharmacy stores End of period 472 Location / During the period New Store Openings 17 / Store closures and business transfers 11 / M&A 9 |
| Medium-term management plan targets | Seventh Medium-Term Management Plan Target fiscal year Fiscal year ending March 2030 / Operating profit 50 Hundreds of millions of yen / ROE 11 % / Number of support cases 25,000 Facility / Market coverage 40 % |
| Financial targets | ROE Actual results for the fiscal year ending March 2026 6.4% / Target for the fiscal year ending March 2030 11% / Target for the fiscal year ending March 2035 15% |
| Annual Dividend | Fiscal year ending March 2026 Annual ¥12 per share / Forecast for the fiscal year ending March 2027 Annual ¥12 per share / Interim and Year-End Breakdown Not disclosed |
| Payout ratio | Fiscal year ending March 2026 32.7 % / Forecast for the fiscal year ending March 2027 35.1 % |
| Acquisition of treasury shares | Flexible share repurchases (the specific repurchase limit, number of shares, and period were Not disclosed) |
| Capital expenditures | 120 JPY hundred million (four-year cumulative plan through the fiscal year ending March 2030) |
| Market Size / Share | Generic drug market size Approximately JPY 1.5 trillion / Market covered by products sold by the company Approximately JPY 540 billion / Market coverage Fiscal year ending March 2026 Approximately 25% / Fiscal year ending March 2030 Approximately 40% / Fiscal year ending March 2035 75～80% |
| New initiatives | Formulation of the 7th Medium-Term Management Plan, Build a customer management platform and establish a cross-selling structure, Organize and standardize service offerings in the food, housing, sleep, and prevention fields, and introduce them at priority stores, Strengthen alliances with manufacturing partners and expand the range of products handled, Promote company-wide digital transformation and integrate customer and transaction data |
Items this document does not state (9)
Gross Profit MarginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased as stores opened in the previous fiscal year contributed to the Community Pharmacy segment, while the customer bases of the pharmaceutical manufacturing and sales and pharmaceutical logistics segments expanded. Operating profit benefited from an increase in support cases in the Pharmacy Support segment and improved profitability in the Pharmaceutical Logistics segment. Factors weighing on profit included higher personnel expenses, a decline in patients with acute illnesses, revisions to drug prices and dispensing fees, and a one-time increase in systems investment.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.